Treace Announces First Surgical Cases Utilizing the SpeedAkin™ Anatomic Compression Implant
January 30 2025 - 8:00AM
Treace Medical Concepts, Inc. (“Treace” or the “Company”)
(NasdaqGS: TMCI), a medical technology company driving a
fundamental shift in the surgical treatment of bunions and related
midfoot deformities through its flagship Lapiplasty® and
Adductoplasty® Procedures, today announced the successful
completion of the first cases utilizing its SpeedAkin™
Anatomic Compression Implant.
The SpeedAkin™ implant broadens the procedural
versatility of Treace’s flagship SpeedPlate™ fixation platform,
which is advancing a new standard in bone fusion fixation. Akin
osteotomies are corrective straightening procedures of the great
toe commonly performed in conjunction with bunion surgery1.
SpeedAkin™ offers surgeons a unique anatomic implant that delivers
dynamic titanium compression to stabilize the Akin osteotomy during
healing.
“The SpeedAkin™ implant leverages our
proprietary SpeedPlate™ technology in a differentiated Akin
osteotomy solution, further expanding our best-in-class bunion
focused portfolio.” said John T. Treace, CEO, Founder and Board
Member of Treace.
Surgeon design team member, Amber Shane, DPM,
FACFAS, Department Chair and Residency Faculty at AdventHealth
commented, “The SpeedAkin™ titanium compression implant provides my
patients the benefits of anatomically contoured fixation and
eliminates the potential for nickel allergy reaction associated
with nitinol staples. SpeedPlate™ technology is a gamechanger for
my Lapiplasty® and Adductoplasty® procedures - and I’m excited to
extend these benefits to my Akin osteotomies, a procedure I perform
frequently with my bunion corrections.”
Internet Posting of
InformationTreace routinely posts information that may be
important to investors in the “Investor Relations” section of its
website at www.treace.com. The Company encourages investors
and potential investors to consult the Treace website regularly for
important information about Treace.
About Treace Medical
ConceptsTreace Medical Concepts, Inc. is a medical
technology company with the goal of advancing the standard of care
for the surgical management of bunion and related midfoot
deformities. Bunions are complex 3-dimensional deformities that
originate from an unstable joint in the middle of the foot and
affect approximately 67 million Americans, of which Treace
estimates 1.1 million are annual surgical candidates. Treace has
pioneered and patented the Lapiplasty® 3D Bunion Correction® System
– a combination of instruments, implants, and surgical methods
designed to surgically correct all three planes of the bunion
deformity and secure the unstable joint, addressing the root cause
of the bunion and helping patients get back to their active
lifestyles. To further support the needs of bunion patients, Treace
has introduced its Adductoplasty® Midfoot Correction System,
designed for reproducible surgical correction of midfoot
deformities. The Company continues to expand its footprint in the
foot and ankle market with the introduction of its SpeedPlate™
Rapid Compression Implants, an innovative fixation platform with
broad versatility across Lapiplasty® and Adductoplasty® procedures,
as well as other common bone fusion procedures of the foot. For
more information, please visit www.treace.com.
- TMC Data on
file
Dr. Amber Shane is a paid consultant of the
Company.
To learn more about Treace, connect with us
on LinkedIn, X, Facebook and Instagram.
Contacts:Treace Medical ConceptsMark L.
HairChief Financial Officermhair@treace.net(904) 373-5940
Investors:Gilmartin GroupVivian
CervantesIR@treace.net
Treace Medical Concepts (NASDAQ:TMCI)
Historical Stock Chart
From Jan 2025 to Feb 2025
Treace Medical Concepts (NASDAQ:TMCI)
Historical Stock Chart
From Feb 2024 to Feb 2025